Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [10]. - The growth was driven by both domestic recovery and overseas expansion, with significant contributions from model animals and preclinical CRO services [10]. - The antibody development platform is progressing well, with numerous collaborations that are expected to enhance future growth potential [10]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 1.379 billion RMB (2025), 1.849 billion RMB (2026), and 2.422 billion RMB (2027), with growth rates of 40.6%, 34.1%, and 31.0% respectively [3][10]. - Net profit forecasts for the same period are 173 million RMB (2025), 335 million RMB (2026), and 528 million RMB (2027), with growth rates of 416.4%, 93.3%, and 57.7% respectively [3][10]. - The earnings per share (EPS) are projected to be 0.39 RMB (2025), 0.75 RMB (2026), and 1.18 RMB (2027) [3][10]. Business Segments - The domestic revenue for the first half of 2025 was 199 million RMB, showing a year-on-year increase of 70.54%, while overseas revenue reached 421 million RMB, up by 43.59% [10]. - Model animals and preclinical CRO services were the main growth drivers, with model animal revenue at 274 million RMB (up 56.13%) and preclinical CRO service revenue at 155 million RMB (up 90.10%) in the first half of 2025 [10]. - The company launched over 400 humanized mouse models in 2025, reinforcing its leading position in the humanized animal model sector [10].

Market Performance - The Sci-Tech Innovation 50 Index opened lower on December 10, fluctuating throughout the day, ultimately closing at 1346.7 points with a slight decline of 0.03% and a total trading volume of approximately 55.36 billion yuan [1] - The overall Sci-Tech Innovation Index rose by 0.14% to close at 1604.56 points, with a total trading volume of 180.3 billion yuan [1] - Among the 595 stocks in the Sci-Tech board, there were more decliners than gainers, with semiconductor and communication equipment stocks performing strongly, while electrical equipment and software service stocks saw significant declines [1] Company Highlights - Bai'ao Saitou was listed on the Sci-Tech board on December 10, with a stock code of 688796 and an issue price of 26.68 yuan per share, resulting in a high price-to-earnings ratio of 519.12 times [1] - Bai'ao Saitou specializes in drug development and preclinical research, offering services such as gene editing, pharmacological efficacy evaluation, model animal sales, antibody development, and innovative drug development [1] - By the end of the trading day, Bai'ao Saitou's stock price increased by 146.6% from its issue price, with a trading volume of approximately 1.67 billion yuan and a turnover rate of 75.8% [1] Stock Performance Analysis - Excluding Bai'ao Saitou's first-day performance, the average increase for the remaining 594 stocks on the Sci-Tech board was approximately 0.01%, with an average turnover rate of 2.37% and a total trading volume of about 178.675 billion yuan [2] - In individual stock performance, Huo Lai Wo reached the daily limit, marking the highest increase, while Jia Hua Technology experienced the largest decline at 10.1% [2] - In terms of trading volume, Mo'er Thread led with a volume of 10.82 billion yuan, while Hanbang Technology had the lowest at 731.4 million yuan [2] - Mo'er Thread also had the highest turnover rate at 51.93%, while Zhongfu Shenying recorded the lowest at 0.14% [2]

Core Viewpoint - Baiaosaitu (688796) has successfully listed on the Sci-Tech Innovation Board, with its stock opening up 117.4% at 58 CNY per share [1] Company Overview - Baiaosaitu is an innovative drug preclinical CRO and biotechnology company, primarily providing antibody drug discovery and preclinical research services [1] - The company's services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [1] Stock Listing Details - Baiaosaitu previously issued H-shares in September 2022 and is listed on the Hong Kong Stock Exchange [1] - Following the A-share public offering, the company will have its stock listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange, with 75.21% of shares circulating in A-shares and 24.79% in H-shares [1] - The proportion of circulating shares in A-shares is higher than that in H-shares [1]

Core Viewpoint - BaiO Saite (688796) is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, with an issue price of 26.68 yuan per share [2]. Company Overview - BaiO Saite is an innovative drug preclinical CRO and biotechnology company, primarily engaged in providing antibody drug discovery and preclinical research services for innovative drug enterprises [2]. - The company's specific services include the sale of innovative model animals, preclinical pharmacology and efficacy evaluation services, and antibody development [2].